Navigation Links
Common drugs linked to cognitive impairment and possibly to increased risk of death
Date:6/24/2011

INDIANAPOLIS A large, long-term study confirms that medications with anticholinergic activity, which include many drugs frequently taken by older adults, cause cognitive impairment. The research is also the first to identify a possible link between these drugs which include over-the-counter and prescription sleep aids and incontinence treatments and risk of death.

The two-year study of the impact of these medications on 13,000 men and women aged 65 and older is part of the Medical Research Council (UK) Cognitive Function and Ageing Studies (CFAS), a large UK-based longitudinal multi-center study initiative looking at health and cognitive function in older adults. Results of the study of anticholinergics appear June 24, 2011 in an advanced online publication of the Journal of the American Geriatrics Society.

Anticholinergics affect the brain by blocking acetylcholine, a nervous system neurotransmitter. Over-the-counter products containing diphenhydramine, sold under various brand names such as Benadryl, Dramamine, Excedrin PM, Nytol, Sominex, Tylenol PM, and Unisom, have anticolinergic activity. Other anticholinergic drugs, such as Paxil, Detrol, Demerol and Elavil are available by prescription.

"Our findings make it clear that clinicians need to review the cumulative anticholinergic burden in people presenting with cognitive impairment to determine if the drugs are causing decline in mental status," said co-author Malaz Boustani, M.D., Regenstrief Institute investigator, Indiana University School of Medicine associate professor of medicine, and research scientist with the IU Center for Aging Research.

"Physicians should review with older patients all the over-the-counter and prescription drugs they are taking to determine exposure," said Dr. Boustani a geriatrician who sees patients at Wishard Health Services' Healthy Aging Brain Center in Indianapolis.

The researchers, led by Chris Fox, M.D., of the University of East Anglia and Carol Brayne, M.D. of the University of Cambridge, used the Anticholinergic Cognitive Burden Scale developed by Dr. Boustani and colleagues at the Regenstrief Institute, Indiana University and in the United Kingdom to evaluate the link between anticholinergic activity and cognitive decline.

Medications with anticholinergic effects are used for many diseases including hypertension and congestive heart failure. The study found that older age, lower income, and greater number of health conditions increased use of medications with anticholinergic activity. Women were more likely to report taking anticholinergic medications, due to the greater number of health conditions reported by women than by men. Participants living in institutions were more likely to report taking anticholinergic medications.

"We looked at drugs with either moderate and severe anticholinergic activity. After adjusting for age, sex, baseline mental status, education, income level, number of non-anticholinergic medications and health conditions, we found that taking anticholinergic medications was linked to cognitive impairment and for the first time to death," said study corresponding author Dr. Fox, a psychiatrist. "We need follow-up to determine the degree to which anticholinergics are being prescribed for diseases with significant risk of death and the impact of that on our findings."

Authors of the study are Chris Fox, M.D., University of East Anglia; Carol Brayne, M.D., Kathryn Richardson, M.Sc. and George M. Savva, Ph.D, University of Cambridge; Ian D. Maidment, M.A., Kent and Medway NHS and Social Care Partnership Trust; Fiona E. Matthews, Ph.D., Medical Research Council Biostatistics Unit; David Smithard, M.D., Kent Community Health NHS Trust; Simon Coulton M.Sc., University of Kent; Cornelius Katona, M.D., University College London and Malaz Boustani, M.D., M.P.H., Regenstrief Institute, Indiana University School of Medicine and IU Center for Aging Research.

"The Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study (CFAS)" was funded by the Medical Research Council.

"The Medical Research Council invests in cohort studies like CFAS because they provide vital clinical information through observation. Such projects require long-term commitment to fulfill their potential but having supported cohort studies for well over half a century, MRC funding and collaborations have made us an international leader in this field," said Chris Kennard, MBBS, Ph.D., chairman of the MRC's Neuroscience and Mental Health Board.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Related medicine news :

1. Diagnosed autism is more common in an IT-rich region
2. Can Weight-Loss Surgery Reverse Common Cause of Infertility?
3. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
4. New research provides breakthrough in understanding common cancer
5. Bursitis a common cause of painful hips, knees, heels and elbows
6. Reducing a severe side effect of a common anticancer drug
7. Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
8. Common test could help predict early death in diabetes, study shows
9. Post-Partum Depression More Common in Abused Women
10. Most common form of inherited intellectual disability may be treatable
11. Hospice Care More Common in Wealthier Areas, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... HireNurses, on the eve of National Nurses Week (May 6-12). Currently, HireNurses ... employers. With their enrollment into the Talent Tech Lab Virtual Incubation program, they will ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet dangerous, ... the immune system and increase inflammation, both of which raise the risk of heart ... heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to ...
(Date:5/5/2016)... Dallas, Texas (PRWEB) , ... May 05, 2016 ... ... and relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the ... Dallas, Texas. , Scott Pettigrew, Vice President and Chief Security Officer of ...
(Date:5/5/2016)... , ... May 05, 2016 , ... If you don’t ... marks on your skin, you may want to consider a treatment that some have ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud to ... new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This ... laser on the market. Jeremy Miller, Tattoo Artist and former reality show contestant ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 ... the  "Europe Systemic Lupus Erythematosus Market and ... their offering.       (Logo: ... research Europe Systemic Lupus Erythematosus Market and ... insights into Systemic Lupus Erythematosus pipeline products, ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 /PRNewswire/ ... announced today that BiondVax,s CEO, Dr. Ron Babecoff , ... New York City . On ... at Pioneers 2016, a conference presented by Joseph Gunner ... Hotel. The BiondVax presentation that Dr. Babecoff will ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
Breaking Medicine Technology: